← Back to Screener
TG Therapeutics, Inc. (TGTX)
Price$36.96
Favorite Metrics
Price vs S&P 500 (26W)-4.10%
Price vs S&P 500 (4W)8.00%
Market Capitalization$5.64B
P/E Ratio (Annual)12.60x
All Metrics
Book Value / Share (Quarterly)$4.17
P/TBV (Annual)3.26x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)504.86%
Cash Flow / Share (Quarterly)$-0.16
Price vs S&P 500 (YTD)14.38%
Gross Margin (TTM)83.66%
Net Profit Margin (TTM)72.56%
EPS (TTM)$2.78
10-Day Avg Trading Volume1.62M
EPS Excl Extra (TTM)$2.78
Revenue Growth (5Y)426.73%
EPS (Annual)$2.77
ROI (Annual)5.01%
Gross Margin (Annual)83.66%
Net Profit Margin (5Y Avg)-2631.07%
Cash / Share (Quarterly)$0.91
P/E Basic Excl Extra (TTM)12.60x
Revenue Growth QoQ (YoY)78.00%
P/E Normalized (Annual)12.60x
ROA (Last FY)4.05%
Revenue Growth TTM (YoY)87.32%
EBITD / Share (TTM)$0.83
ROE (5Y Avg)-112.83%
Operating Margin (TTM)20.01%
Cash Flow / Share (Annual)$-0.26
P/B Ratio8.70x
P/B Ratio (Quarterly)7.30x
Net Income / Employee (Annual)$1
EV / Revenue (TTM)9.41x
Net Interest Coverage (TTM)5.02x
ROA (TTM)51.88%
EPS Growth QoQ (YoY)-0.69%
EV / EBITDA (TTM)43.24x
EPS Incl Extra (Annual)$2.77
Current Ratio (Annual)6.25x
Quick Ratio (Quarterly)3.29x
3-Month Avg Trading Volume1.93M
52-Week Price Return-7.54%
P/E Incl Extra (TTM)12.60x
Revenue / Employee (TTM)$2
Tangible BV / Share (Quarterly)$1.17
P/S Ratio (Annual)9.14x
Asset Turnover (Annual)0.57x
52-Week High$46.48
Operating Margin (5Y Avg)-2590.34%
EPS Excl Extra (Annual)$2.77
CapEx CAGR (5Y)-9.73%
Tangible BV CAGR (5Y)-2.68%
26-Week Price Return4.65%
Quick Ratio (Annual)5.03x
13-Week Price Return19.60%
Total Debt / Equity (Annual)1.10x
Current Ratio (Quarterly)4.10x
Enterprise Value$5,801.895
Revenue / Share Growth (5Y)393.83%
Asset Turnover (TTM)0.71x
Book Value / Share Growth (5Y)32.23%
Revenue / Employee (Annual)$2
Pretax Margin (Annual)17.43%
Cash / Share (Annual)$2.00
3-Month Return Std Dev41.60%
Gross Margin (5Y Avg)88.92%
Net Income / Employee (TTM)$1
ROE (Last FY)10.52%
Net Interest Coverage (Annual)5.02x
EPS Basic Excl Extra (Annual)$2.77
P/FCF (TTM)208.82x
Receivables Turnover (TTM)2.83x
Total Debt / Equity (Quarterly)0.38x
EPS Incl Extra (TTM)$2.78
Receivables Turnover (Annual)3.65x
ROI (TTM)65.05%
P/S Ratio (TTM)9.14x
Pretax Margin (5Y Avg)-2641.92%
Revenue / Share (Annual)$3.82
Tangible BV / Share (Annual)$1.17
Forward P/E27.32x
Price vs S&P 500 (52W)-42.63%
P/E Ratio (TTM)12.60x
EPS Growth TTM (YoY)1889.26%
Year-to-Date Return18.52%
5-Day Price Return4.56%
EPS Normalized (Annual)$2.77
ROA (5Y Avg)-48.82%
Net Profit Margin (Annual)72.56%
Month-to-Date Return6.35%
Cash Flow / Share (TTM)$-0.18
EBITD / Share (Annual)$0.83
Operating Margin (Annual)20.01%
LT Debt / Equity (Annual)1.10x
ROI (5Y Avg)-65.52%
P/E Excl Extra (TTM)12.60x
LT Debt / Equity (Quarterly)0.38x
EPS Basic Excl Extra (TTM)$2.78
P/TBV (Quarterly)3.26x
P/B Ratio (Annual)21.07x
Inventory Turnover (TTM)0.85x
Pretax Margin (TTM)17.43%
Book Value / Share (Annual)$1.43
Price vs S&P 500 (13W)16.74%
Beta1.73x
Revenue / Share (TTM)$3.87
ROE (TTM)101.12%
52-Week Low$25.28
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.93
3.93
3.93
3.93
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TGTXTG Therapeutics, Inc. | 9.14x | 87.32% | 83.66% | — | $36.96 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
TG Therapeutics is a biopharmaceutical company specializing in B-cell disease treatments, with FDA-approved BRIUMVI (ublituximab-xiiy) for relapsing multiple sclerosis generating revenue primarily in the United States. The company is advancing a pipeline of early-stage therapies including TG-1701 (BTK inhibitor), Azer-Cel (CAR T-cell therapy), and TG-1801 (bispecific antibody) for various B-cell disorders.